A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So
A phase 1/2 trial of RO7771950, Pertuzumab in her2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05593094 by Hoffmann-La Roche, with 210 participants planned, started 2020-09-03 and due to reach its primary completion in 2027-08-31. Interventions recorded: ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c. Conditions listed: Advanced Solid Tumors, HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Shares RO7771950, Roche / Genentech, HER2-positive breast cancer.
- TrialA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer.
- TrialClinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Pertuzumab, HER2-positive breast cancer.
- TrialStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Shares Pertuzumab, HER2-positive breast cancer.
- TrialA Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive
Shares Pertuzumab, HER2-positive breast cancer.
- TrialDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer.